title: [Volume regulation in cardiac insufficiency : possibilities of telephone coaching and peritoneal dialysis].
abstract: Volume retention is the hallmark of progressive heart failure, both systolic and diastolic (heart failure with preserved ejection fraction). It represents the cause of the main symptoms (dyspnea, edema, liver synthesis) and also the main target of drug therapy. Antagonizing excessive volume retention is also the most important therapy element. Many patients can be stabilized with sequential nephron blockade (thiazide + loop diuretics) combined with afterload reduction [blockade of the RAAS (renin-angiotensin-aldosterone) system]. Personal patient coaching combined with telemetric components (weight, blood pressure) has evolved as another cornerstone of treatment in heart failure patients. If these measures are insufficient to control volume retention, renal replacement therapy is effective and can improve quality of life. More specifically, aquaresis via peritoneal dialysis has been shown to be effective and adequate to control volume overload. Many patients may qualify for this evolving therapy as it effectively prevents repeat hospitalization for heart failure decompensation, can be performed in an out-patient setting and has a low complication rate, thus significantly improving quality of life.
authors.affiliation: Abt. Kardiologie, Asklepios Klinik St. Georg, Hamburg, Deutschland. mar.bergmann@asklepios.com
authors.forename: M W
authors.initials: MW
authors.lastname: Bergmann
authors.forename: K-H
authors.initials: KH
authors.lastname: Kuck
authors.forename: I
authors.initials: I
authors.lastname: Krenz
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001810:Blood Volume / Q000187:drug effects / Q000502:physiology*; D003131:Combined Modality Therapy; D004232:Diuretics / Q000627:therapeutic use; D004489:Edema, Cardiac / Q000503:physiopathology* / Q000628:therapy*; D054144:Heart Failure, Diastolic / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D054143:Heart Failure, Systolic / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D010353:Patient Education as Topic / Q000379:methods*; D010359:Patient Readmission; D010530:Peritoneal Dialysis / Q000379:methods*; D015996:Survival Rate; D013689:Telephone
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics